Genetic polymorphisms in human GSTO1 and GSTO2 genes have been implicated in neurodegenerative diseases such as Alzheimer's and Parkinson's, and the levels of GSTO2 expression were described to be reduced in patients affected by these pathologies. This evidence concerns the gene GSTO2 and Parkinson disease.